EP0801676A2 - New artificial tissue, method for the production and the use thereof - Google Patents
New artificial tissue, method for the production and the use thereofInfo
- Publication number
- EP0801676A2 EP0801676A2 EP96941582A EP96941582A EP0801676A2 EP 0801676 A2 EP0801676 A2 EP 0801676A2 EP 96941582 A EP96941582 A EP 96941582A EP 96941582 A EP96941582 A EP 96941582A EP 0801676 A2 EP0801676 A2 EP 0801676A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- tissue
- cell
- differentiating
- tissues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0655—Chondrocytes; Cartilage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/04—Screening or testing on artificial tissues
Definitions
- the invention relates to new artificial tissues, processes for their production and their use and cell interaction systems for inducing artificial tissues for the purpose of producing vital grafts and for establishing disease models.
- Such cell interaction culture systems for in vitro organ and tissue models are suitable for the production of three-dimensional cell tissue with the aid of three-dimensional carrier structures which allow the formation of an extracellular matrix (ECM), but initially do not yet have an ECM.
- ECM extracellular matrix
- Numerous cell culture systems are known in which an extracellular matrix (ECM) has been described.
- Patent document DE 3410631 presents an implantation material for restoring defective cartilage or bone, which is either in gel form or embedded in natural or artificial bone material.
- the gel contains embryonic species-specific chondrocytes or mesenchymal cells and preferably also an extracellular matrix of chondrocytes and growth hormones.
- US Pat. No. 4801299 proposes body implants in the form of an extracellular matrix based on collagen.
- a method for tissue regeneration with the help of an extracellular matrix induction forms the subject of US 4935000.
- Extracellular matrices continue to be found in connection with the restoration of human skin, cosmetic compositions (US 5055298) and on a collagen or fibronectin basis for attaching T- Cells (US 5188959 and 5354686) use.
- DE 4336399 describes collagen (type I) as the basic matrix for the stationary phase of bipolar adhered hepatocytes in a cell culture.
- the functional immobilization of enzymes, proteins and whole cells on solid, biocompatible carrier materials by means of electrostatic interaction between the surface coating of the solid and the adsorbate to be fixed forms the subject of DE 4323487.
- WO 92/20780 (DE 4116727), the simultaneous cultivation is different Mammalian cells, the separate extraction of different mammalian cell products and the modeling of organ interactions on a humoral level are described.
- methods have become known which start from polymer fiber bundles made of resorbable material, onto which isolated and expanded cells are placed and the bundles are implanted.
- WO 90/12603 mentions three-dimensional support structures which are designed in the form of the organ to be replaced and are mixed with the desired cells. With three-dimensional support structures, however, there is a difficulty in providing the cells inside the implant with sufficient nutrients.
- the invention has for its object to provide new artificial tissues, to develop processes for their manufacture and to enable their medical use.
- new artificial interacting tissues consist of new three-dimensional extracellular matrices (ECM) in networkable structures, cell interaction systems for the induction of artificial three-dimensional tissues as well as genetically manipulated cells that release immunosuppressive or cell-differentiating factors.
- ECM extracellular matrices
- cell interaction systems are used to induce artificial three-dimensional tissues in such a way that cultures which have or develop an extracellular matrix are connected to one another via membranes or are in direct contact or mixed with one another.
- an artificial cell tissue for example cartilage or bone tissue
- the task of stabilizing the grafts was achieved by genetic manipulation of cells, in particular in that human cells were equipped with certain genes, for example bone morphogenic protein, interleukin-1 receptor antagonist or TGF- ⁇ , and then became one new cartilage tissues are grown.
- the invention consists of a combination of new and known elements that work together to create products with new and improved properties.
- the cell interaction system according to the invention (FIG. 1) consists of the nutrient solution / the cooling container 1, the drop formation chamber 2, the mixing chamber 3, the perfusion chamber 4 (with hot plate), the quantity measuring device 5 (optical control), the sampling 6, the medium outlet chamber 7 and the interface / PC 8.
- three-dimensional cell tissue with the help of three-dimensional support structures, eg absorbable polymer nonwovens.
- a cartilage tissue e.g. undifferentiated (increased) cartilage cells or undifferentiated mesenchymal progenitor cells are used. Differentiated cartilage cells from the patient are usually only available in small quantities (surgical intervention necessary).
- an undifferentiated cell suspension is mixed with the body's own cells or cell aggregates of a defined (differentiated) phenotype, b) defined (e.g. differentiated) or genetically manipulated foreign cells are suspended in a gel or fleece and around the tissue or stored directly on the tissue to be differentiated.
- the arrangement of this method creates a defined contact zone between two artificial three-dimensional cell tissues. This contact zone serves as a test system for diseases. At the border zones, line and matrix changes, e.g. when administering medication.
- the interaction cell culture systems according to the invention are suitable for use as in vitro organ and tissue models.
- the induction of an artificial cell tissue into cartilage or bone tissue by transfected cell cultures or three-dimensional cultures of periosteal or perichondrium cells which have an extracellular Develop or own a matrix allow the construction of models for diseases in which the extracellular matrix plays a role.
- the new interacting artificial tissues are used to produce vital grafts that are suitable for in-vitro simulation of pathogenic and infectious processes, for establishing disease models and for testing active substances.
- FIG. 2 shows row and tissue arrangements.
- Serial culture factors from the tissue (left) act on the tissue on the right. The factor from the tissue on the right does not affect the tissue on the left.
- Sandwich culture Two or more artificial tissues lie on top of or next to each other (contact zones). Integrated culture. It is a mixture of different ones
- Flowing cells A mixture of suspended cells (e.g. lymphocytes or microorganisms) flows along an artificial tissue (e.g.
- Endothelium and adhere there when the cells express suitable receptors.
- Figure 3 - Top picture: The purpose of the cell mixture is to differentiate as many of the undifferentiated cells as possible with the few differentiated or differentiating cells. 80% of the undifferentiated mesenchymal cells and 20% of the differentiated cartilage cells are together in one tissue (tissue 1). Non-body or genetically manipulated cells are arranged around the tissue 1 if they produce differentiating factors.
- the transplantable cartilaginous tissues stabilized according to the invention consist of a new extracellular matrix (ECM) in three-dimensional structures, of increased nodule cells, of crosslinkable / polymerizable polypeptides or polysaccharides and of cells which, due to genetic engineering, release matrix molecules, immunosuppressive or cell-differentiating factors.
- ECM extracellular matrix
- Their structures are composed of three-dimensional fiber structures, three-dimensional tissues, fibrin and a semipermeable membrane surrounding the artificial knot system.
- a desired shape is composed, for example, of a silicone negative, chamfer wool or fiber structures made of resorbable polymers, such as a-hydroxy acids, and the semi-permeable membrane made of polyelectrolyte complexes, such as polylysine or hyaluronic acid.
- the process for the production of transplantable knot tissue consists in that knotty cell suspensions containing polymerizable solutions and gene therapy modified cells are filled in three-dimensional structures, solidified with thrombin or polymerization-inducing factors, the cells in this three-dimensional structure produce a new extracellular matrix (ECM) and the knot system with semipermeable membrane is surrounded.
- ECM extracellular matrix
- the polymerizable solutions consist of crosslinkable / polymerizable polypeptides or polysaccharides and the modified cells from those that release matrix molecules, immunosuppressive or cell-differentiating factors due to genetic engineering manipulation.
- Fibrinogen is used as the polypeptide in such a way that cell suspensions containing fibrinogen are filled into structures made from three-dimensional fiber structures or from three-dimensional tissues and solidified with thrombin. The fibrinogen is obtained from the patient from whom the cells originate and / or into which the three-dimensional knot tissue is to be implanted.
- all or part of the cells are genetically modified with one or more of the following genes: TGF-ß, bone morphogenetic proteins, morphogenes, receptors for morphogenes, anti-inflammatory cytokines, cytokine antagonists such as IL-1 antagonists, IL-1 receptor antagonists, TNF antagonists or with protease inhibitors (TIMP, PAI).
- TGF-ß bone morphogenetic proteins
- morphogenes morphogenes
- receptors for morphogenes anti-inflammatory cytokines
- cytokine antagonists such as IL-1 antagonists, IL-1 receptor antagonists, TNF antagonists or with protease inhibitors (TIMP, PAI).
- TGF-ß transforming growth factor-1
- morphogenes morphogenes
- receptors for morphogenes anti-inflammatory cytokines
- cytokine antagonists such as IL-1 antagonists, IL-1 receptor antagonists, TNF antagonists or with protease inhibitors (TIM
- Another feature of the invention is that genetically manipulated and unchanged cells are introduced into separate artificial tissues and shaped and combined to form a total tissue or shaped tissues with genetically manipulated cells and tissues with unchanged cells in layers or by wrapping or two or more tissues with each different genetic manipulations can be combined in layers or by wrapping. Tissues containing genetically manipulated cells can be combined with tissues containing genetically unmodified cells.
- the cartilage tissue produced according to the invention has in particular immunosuppressive properties. It has surprisingly been found that the invention
- Kno ⁇ elgewebe is suitable and that the Kno ⁇ elelgewebe invention can be used for the therapy of Kno ⁇ lschamels in patients with rheumatoid arthritis. It is also surprising that the semipermeable membrane used in accordance with the invention, with which the produced cartilage tissue is surrounded before, during and for some time after the implantation, offers protection against immunological and dedifferentiating
- Example 1 Three-dimensional cell tissue A three-dimensional cell tissue is produced with the aid of three-dimensional carrier structures (resorbable polymer fleece). (A) undifferentiated (increased) nodule cells or (b) undifferentiated mesenchymal progenitor cells are used for the production of a nodular tissue. The cells to be distributed in the fleece structure are first suspended in a fibrinogen solution. The cell suspension is filled into the fleece carrier and solidified by adding thrombin.
- three-dimensional carrier structures resorbable polymer fleece.
- the differentiating micro environment can be any suitable material.
- Tissue components that produce or release paracrine kno ⁇ el-differentiating factors are created.
- factors are e.g. bone mo ⁇ hogenetic proteins, cartilage drived mo ⁇ hogenetic proteins, transformig growth factor beta (Luvten, F.P. et al.,
- the arrangement of this method creates a defined contact zone between two artificial three-dimensional cell tissues. 0
- Increased nodule cells or mesenchymal progenitor cells of different degrees of maturation and differentiation are suspended in a fibrinogen solution, the cell suspension is distributed in a resociable polymer fleece, factors or components of the corresponding extracellular matrix that are conducive to the growth and differentiation process are added and solidified by adding thrombin and differentiating Exposed to micro-milieu.
- Cells of osteogenic origin of different maturation and differentiation levels 5 or mesenchymal progenitor cells are suspended in a fibrinogen solution, the cell suspension is distributed in a reso ⁇ ie ⁇ aren polymer construct, factors or components of the corresponding extracellular matrix, which are conducive to the growth and differentiation process, added and solidified by adding thrombin and exposed to a differentiating micro environment.
- Example 7 Transplantation of artificially produced cartilage tissue for the therapy of cartilage damage in patients with rheumatoid arthritis
- Mesenchymal cells of a patient's tissue sample are sufficiently grown in vitro in monolayer culture and partially transfected with a gene for BMP (bone mo ⁇ hogenetic protein).
- the cells are suspended in a fibrinogen-containing solution and then placed in a carrier structure (for example resorbable polymer nonwovens made of polylactide and polyglycolide).
- the suspension is then solidified in the structure by adding thrombin.
- the tissue can be transplanted into the patient's joint immediately or after in vitro maturation.
- Example 8 Other Artificial Tissues - Bones, Liver, Kidney, Vessels, Skin Comparable to Example 1, part of the cells are manipulated with a desired gene and this gene therapy-modified population is brought into a specific form using carrier structures and fibrin. Genetically unmodified cells are then attached to this structure, likewise using shaping structures, so that a diffusion and thus activity gradient for genetically introduced active substances can act on the untreated cells. This serves to polarize the tissue structures produced in vitro, comparable to the polarization in the native articular cartilage.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19540487 | 1995-10-20 | ||
DE19540487A DE19540487A1 (en) | 1995-10-20 | 1995-10-20 | Cell interaction system for induction of artificial 3-dimensional tissue |
DE19632404 | 1996-08-02 | ||
DE19632404A DE19632404A1 (en) | 1996-08-02 | 1996-08-02 | Artificial tissue comprising three-dimensional extracellular matrix, cell interaction system |
PCT/DE1996/002025 WO1997015655A2 (en) | 1995-10-20 | 1996-10-18 | New artificial tissue, method for the production and the use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0801676A2 true EP0801676A2 (en) | 1997-10-22 |
Family
ID=26019940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96941582A Withdrawn EP0801676A2 (en) | 1995-10-20 | 1996-10-18 | New artificial tissue, method for the production and the use thereof |
Country Status (4)
Country | Link |
---|---|
US (2) | US5932459A (en) |
EP (1) | EP0801676A2 (en) |
JP (1) | JP3452366B2 (en) |
WO (1) | WO1997015655A2 (en) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020173806A1 (en) * | 1996-08-30 | 2002-11-21 | Verigen Transplantation Service International (Vtsi) Ag | Method for autologous transplantation |
US6569172B2 (en) | 1996-08-30 | 2003-05-27 | Verigen Transplantation Service International (Vtsi) | Method, instruments, and kit for autologous transplantation |
US5989269A (en) | 1996-08-30 | 1999-11-23 | Vts Holdings L.L.C. | Method, instruments and kit for autologous transplantation |
US20060025786A1 (en) * | 1996-08-30 | 2006-02-02 | Verigen Transplantation Service International (Vtsi) Ag | Method for autologous transplantation |
DE69714035T2 (en) | 1997-08-14 | 2003-03-06 | Sulzer Innotec Ag, Winterthur | Composition and device for repairing cartilage tissue in vivo consisting of nanocapsules with osteoinductive and / or chondroinductive factors |
US6171610B1 (en) | 1998-04-24 | 2001-01-09 | University Of Massachusetts | Guided development and support of hydrogel-cell compositions |
TR200200089T2 (en) * | 1998-08-14 | 2002-06-21 | Verigen Transplantation Service International (Vtsi) Ag | Methods for chondrocyte cell transplantation; instruments and substances |
US7001746B1 (en) | 1999-01-29 | 2006-02-21 | Artecel Sciences, Inc. | Methods and compositions for the differentiation of human preadipocytes into adipocytes |
US6197061B1 (en) * | 1999-03-01 | 2001-03-06 | Koichi Masuda | In vitro production of transplantable cartilage tissue cohesive cartilage produced thereby, and method for the surgical repair of cartilage damage |
DE19911326A1 (en) * | 1999-03-15 | 2000-09-28 | Fege Wolfgang | Device for growing human or animal tissue |
US6312952B1 (en) * | 1999-05-27 | 2001-11-06 | The Research Foundation Of State University Of New York | In vitro cell culture device including cartilage and methods of using the same |
US20020116063A1 (en) * | 1999-08-02 | 2002-08-22 | Bruno Giannetti | Kit for chondrocyte cell transplantation |
US7005274B1 (en) * | 1999-09-15 | 2006-02-28 | Migenix Corp. | Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass |
EP1099443A1 (en) | 1999-11-11 | 2001-05-16 | Sulzer Orthopedics Ltd. | Transplant/implant device and method for its production |
US7582292B2 (en) | 2000-02-26 | 2009-09-01 | Artecel, Inc. | Adipose tissue derived stromal cells for the treatment of neurological disorders |
EP1918366A1 (en) | 2000-02-26 | 2008-05-07 | Artecel, Inc. | Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof |
ES2300320T3 (en) * | 2000-02-26 | 2008-06-16 | Artecel, Inc. | PLURIPOTENT MOTHER CELLS GENERATED FROM STROMA CELLS DERIVED FROM ADIPOSE TISSUE AND ITS USES. |
US7174339B1 (en) | 2000-03-07 | 2007-02-06 | Tririga Llc | Integrated business system for the design, execution, and management of projects |
DE10021627B4 (en) | 2000-05-04 | 2009-11-19 | Corlife Gbr (Vertretungsberechtigte Gesellschafter: Prof. Dr. Alex Haverich | Method for producing a vascularized bioartificial tissue and associated experimental reactor |
DE10032808A1 (en) * | 2000-06-30 | 2002-01-17 | Tom Witascheck | Bioreactor growing tissue or complete organ implants by assembly of differing cell types in specific forms and patterns, includes chambers with cavities of differing shape |
US6719970B1 (en) | 2000-07-10 | 2004-04-13 | Alkermes Controlled Therapeutics, Inc. | Method of generating cartilage |
DE10038700B4 (en) * | 2000-07-31 | 2006-09-07 | Michael Priv.-Doz. Dr. Sittinger | Autologous connective tissues, process for their preparation and their use |
WO2002037395A2 (en) * | 2000-10-30 | 2002-05-10 | Tririga, Inc. | Item specification object management system |
DE10105420B4 (en) * | 2001-01-31 | 2006-03-30 | Transtissue Technologies Gmbh | In vitro cell interaction culture system for drug testing and development |
US7069267B2 (en) * | 2001-03-08 | 2006-06-27 | Tririga Llc | Data storage and access employing clustering |
US7252982B2 (en) * | 2001-03-15 | 2007-08-07 | Massachusetts Institute Of Technology | Tissue engineering enhanced by the transfer of a growth factor gene |
AU2002335747B2 (en) | 2001-09-15 | 2009-01-29 | Rush University Medical Center | Stratified cartilage tissue and methods to engineer same |
US8501396B2 (en) | 2001-11-05 | 2013-08-06 | Medgenics Medical Israel Ltd. | Dermal micro-organs, methods and apparatuses for producing and using the same |
US7468242B2 (en) | 2001-11-05 | 2008-12-23 | Medgenics, Inc. | Dermal micro organs, methods and apparatuses for producing and using the same |
US8088568B2 (en) * | 2001-11-05 | 2012-01-03 | Medgentics, Inc. | Dermal micro-organs, methods and apparatuses for producing and using the same |
US20030165473A1 (en) * | 2001-11-09 | 2003-09-04 | Rush-Presbyterian-St. Luke's Medical Center | Engineered intervertebral disc tissue |
AU2003211750A1 (en) * | 2002-03-08 | 2003-09-22 | Osteogenesis Co., Ltd. | Tissue-forming composition |
US7622562B2 (en) | 2002-06-26 | 2009-11-24 | Zimmer Orthobiologics, Inc. | Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue |
US20040136968A1 (en) * | 2002-09-27 | 2004-07-15 | Verigen Ag | Autologous cells on a support matrix for tissue repair |
JP5128813B2 (en) | 2003-05-01 | 2013-01-23 | メドジニックス・インコーポレイテッド | Dermal organelles and methods and instruments for making and using the same |
US20050130254A1 (en) | 2003-12-16 | 2005-06-16 | Park Sung-Soo | Drug testing system with bio-artificial liver |
US20070048732A1 (en) * | 2005-08-30 | 2007-03-01 | Hepahope, Inc. | Chemosensitivity tester |
WO2007083504A1 (en) * | 2003-08-01 | 2007-07-26 | Norimasa Nakamura | Scaffold-free self-organized 3d synthetic tissue |
US8916184B2 (en) | 2003-11-07 | 2014-12-23 | University Of Connecticut | Artificial tissue systems and uses thereof |
US8071373B2 (en) | 2004-04-28 | 2011-12-06 | Sanofi Pasteur Vaxdesign Corp. | Co-culture lymphoid tissue equivalent (LTE) for an artificial immune system (AIS) |
US8298824B2 (en) | 2004-04-28 | 2012-10-30 | Sanofi Pasteur Vaxdesign Corporation | Methods of evaluating a test agent in a diseased cell model |
DE102005030614B4 (en) | 2005-06-30 | 2014-05-08 | Biotissue Ag | Cell-free graft, its use, process for its preparation, matrix thus produced with gel and process for the preparation of this matrix with gel |
AU2006282872A1 (en) * | 2005-08-24 | 2007-03-01 | Hepahope, Inc. | Novel enhanced processes for drug testing and screening using human tissue |
JP5622358B2 (en) * | 2005-12-21 | 2014-11-12 | サノフィ パスツール ヴァックスデザインコーポレーション | in vitro germinal center |
WO2008031882A1 (en) * | 2006-09-14 | 2008-03-20 | Probiogen Ag | Modular culture system for maintenance, differentiation and proliferation of cells |
EP2061515A4 (en) * | 2006-09-14 | 2013-01-30 | Medgenics Medical Israel Ltd | Long lasting drug formulations |
US8454948B2 (en) | 2006-09-14 | 2013-06-04 | Medgenics Medical Israel Ltd. | Long lasting drug formulations |
DE102006047346A1 (en) | 2006-10-06 | 2008-04-10 | Transtissue Technologies Gmbh | Matrix gel graft without cells |
EP1987804B1 (en) * | 2007-05-02 | 2010-12-29 | Klinikum Mannheim GmbH | Implantable system for an intervertebral disc and intervertebral disc implant |
RU2555336C2 (en) | 2009-01-08 | 2015-07-10 | Байо Дг, Инк. | Implanted medical device, containing biodegradable alloys |
US9511093B2 (en) * | 2009-03-23 | 2016-12-06 | The Texas A & M University System | Compositions of mesenchymal stem cells to regenerate bone |
WO2010123500A1 (en) * | 2009-04-22 | 2010-10-28 | University Of Utah Research Foundation | Methods of making and using three-dimensional extracellular matrices |
KR102173873B1 (en) | 2009-11-12 | 2020-11-04 | 브이셀 세라퓨틱스 인코포레이티드 | Subpopulations of spore-like cells and uses |
EP2582396A4 (en) | 2010-06-15 | 2014-01-01 | Medgenics Medical Israel Ltd | Long lasting drug formulations |
US10130288B2 (en) | 2013-03-14 | 2018-11-20 | Cell and Molecular Tissue Engineering, LLC | Coated sensors, and corresponding systems and methods |
DK2968657T3 (en) | 2013-03-14 | 2019-08-26 | Bio Dg Inc | IMPLANTABLE MEDICAL DEVICES INCLUDING BIOLOGICALLY DEGRADABLE ALLOYS AT INCREASED DEGRADING RATES |
US10405961B2 (en) | 2013-03-14 | 2019-09-10 | Cell and Molecular Tissue Engineering, LLC | Coated surgical mesh, and corresponding systems and methods |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5032508A (en) * | 1988-09-08 | 1991-07-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
US5266480A (en) * | 1986-04-18 | 1993-11-30 | Advanced Tissue Sciences, Inc. | Three-dimensional skin culture system |
US5736372A (en) * | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
US4904259A (en) * | 1988-04-29 | 1990-02-27 | Samuel Itay | Compositions and methods for repair of cartilage and bone |
US5308764A (en) * | 1988-06-30 | 1994-05-03 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Multi-cellular, three-dimensional living mammalian tissue |
WO1994009118A1 (en) * | 1992-10-13 | 1994-04-28 | The General Hospital Corporation | Immortalized human chondrocytes |
US5478739A (en) * | 1992-10-23 | 1995-12-26 | Advanced Tissue Sciences, Inc. | Three-dimensional stromal cell and tissue culture system |
DE4306661C2 (en) * | 1993-03-03 | 1995-04-20 | Michael Dipl Biol Sittinger | Process for producing an implant from cell cultures |
US5712161A (en) * | 1993-12-30 | 1998-01-27 | Nitta Gelatin Inc. | Method for culturing animal cells in collagen drops on a support |
WO1995030742A1 (en) * | 1994-05-05 | 1995-11-16 | Genzyme Corporation | Methods and compositions for the repair of articular cartilage defects in mammals |
US5741685A (en) * | 1995-06-07 | 1998-04-21 | Children's Medical Center Corporation | Parenchymal cells packaged in immunoprotective tissue for implantation |
-
1996
- 1996-10-18 JP JP51620297A patent/JP3452366B2/en not_active Expired - Fee Related
- 1996-10-18 US US08/860,111 patent/US5932459A/en not_active Expired - Lifetime
- 1996-10-18 WO PCT/DE1996/002025 patent/WO1997015655A2/en not_active Application Discontinuation
- 1996-10-18 EP EP96941582A patent/EP0801676A2/en not_active Withdrawn
-
1999
- 1999-03-16 US US09/268,894 patent/US6143501A/en not_active Expired - Lifetime
Non-Patent Citations (1)
Title |
---|
See references of WO9715655A2 * |
Also Published As
Publication number | Publication date |
---|---|
JP3452366B2 (en) | 2003-09-29 |
US6143501A (en) | 2000-11-07 |
US5932459A (en) | 1999-08-03 |
WO1997015655A2 (en) | 1997-05-01 |
WO1997015655A3 (en) | 1997-06-12 |
JPH10511884A (en) | 1998-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997015655A2 (en) | New artificial tissue, method for the production and the use thereof | |
DE10139783C1 (en) | Cell compositions for the treatment of osteoarthritis, and methods for their production | |
EP1242129B1 (en) | Biological joint construct | |
DE69221837T2 (en) | IN VIVO SECRETION OF ACTIVE FACTORS BY CO-CULTIVATED CELL IMPLANTS | |
DE69626560T2 (en) | Laminar bone base for cartilage growth | |
WO2001068811A2 (en) | Method for in vitro production of three-dimensional vital cartilage or bone tissue and use thereof as transplant material | |
EP1792980B1 (en) | Collagen biomatrix and methods to poduce it | |
WO2005113747A2 (en) | Multicellular tissue and organ culture systems | |
DE60016288T2 (en) | INSULATION OF PRECURSOR CELLS AND THEIR USE FOR THE REINFORCEMENT OF BIND WEAVE | |
DE60017757T2 (en) | HUMANIZED BIOMATERIALS CONTAINING MONOCYTES OR MACROPHAGES, A METHOD OF PREPARING THEM AND THEIR APPLICATIONS | |
DE10214095C1 (en) | Producing dedifferentiated, programmable stem cells of human monocytic origin using culture medium having M-CSF and IL-3, useful in treating cirrhosis, pancreatic insufficiency, kidney failure, cardiac infarction and stroke | |
DE19540487A1 (en) | Cell interaction system for induction of artificial 3-dimensional tissue | |
CA2380943C (en) | Mechanically elongated neuronal cells and methods for producing and using these cells | |
WO2004042038A1 (en) | Method for the treatment of diseased, degenerated, or damaged tissue using three-dimensional tissue produced in vitro in combination with tissue cells and/or exogenic factors | |
DE102007005946A1 (en) | Therapeutic composition and use of a cell-free substance | |
DE19632404A1 (en) | Artificial tissue comprising three-dimensional extracellular matrix, cell interaction system | |
EP1287118B1 (en) | Method for producing a recipient-specific tissue transplant or tissue implant | |
Zheng | Myogenic differentiation of human myoblasts, ADSC, and schwann cells on PCL-collagen I-nanofibers | |
Ferner | Influence of microscaffolds on the physical behavior of spheroids. | |
DE10313284A1 (en) | Vascularized tissue substitute useful for repairing tumor-induced defects in the mouth, jaw and facial region comprises microparticles colonized by stroma cells together with endothelial cells in a fibrin matrix | |
Habisch | Cell assemblies formed by multiple culture methods for use in neural tissue engineering |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH ES FR GB IT LI NL |
|
17P | Request for examination filed |
Effective date: 19970918 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: TRANSTISSUE TECHNOLOGIES GMBH |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: HAEUPL, THOMAS Inventor name: BURMESTER, GERD R., PROF. DR. Inventor name: SCHULTZ, OLAF Inventor name: SITTINGER, MICHAEL, DR. |
|
17Q | First examination report despatched |
Effective date: 20030521 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: HAEUPL, THOMAS Inventor name: BURMESTER, GERD R., PROF. DR. Inventor name: SCHULTZ, OLAF Inventor name: SITTINGER, MICHAEL, DR. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20080219 |